(Q39324161)

11 September 2017

1 reference

title

Advancing Immunotherapy in Metastatic Breast Cancer (English)

1 reference

11 September 2017

1 reference

Sherene Loi

4

0 references

author name string

Mariam Mansour

series ordinal

1

1 reference

11 September 2017

Zhi Ling Teo

series ordinal

2

1 reference

11 September 2017

Stephen J Luen

series ordinal

3

1 reference

11 September 2017

publication date

1 June 2017

1 reference

Current Treatment Options in Oncology

11 September 2017

published in

1 reference

11 September 2017

volume

18

1 reference

11 September 2017

issue

6

1 reference

11 September 2017

page(s)

35

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-017-0478-9

11 September 2017

exact match

0 references

cites work

Global Cancer Incidence and Mortality Rates and Trends--An Update

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Breast cancer in 2014: A call back to reality!

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Highlights in breast cancer from ASCO 2016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Combination versus sequential single agent chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Relevance of tumor-infiltrating lymphocytes in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Leukocyte composition of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

The PD-1 pathway in tolerance and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Immune parameters affecting the efficacy of chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

The convergence of radiation and immunogenic cell death signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Anti-vascular endothelial growth factor therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

A novel function for programmed death ligand-1 regulation of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Targeting AKT signaling sensitizes cancer to cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Activation of Akt as a mechanism for tumor immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Immunoregulatory functions of mTOR inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Regulation of immune responses by mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

The role of mTOR in memory CD8 T-cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0478-9

CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion

21 January 2018

1 reference

12 December 2020

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

1 reference

12 December 2020

Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer

1 reference

12 December 2020

Lymphocyte infiltrates as a prognostic variable in female breast cancer

1 reference

12 December 2020

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

1 reference

12 December 2020

Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy

1 reference

12 December 2020

A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1.

1 reference

12 December 2020

Anti-vascular endothelial growth factor therapy in breast cancer: game over?

1 reference

12 December 2020

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

12 December 2020

Programmed cell removal: a new obstacle in the road to developing cancer

1 reference

12 December 2020

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

1 reference

12 December 2020

10.1007/S11864-017-0478-9

Identifiers

DOI

1 reference

11 September 2017

1 reference